2025-06-02-艾昆纬-实现双赢_通过战略规划设计更具代表性的试验（英）_12页_2mb

White Paper Summary: Achieving a Win-Win Through Representative Clinical Trial Design

Based on the "White Paper: Achieving a Win-Win: Designing More Representative Trials Through Strategic Planning" by IQVIA, here is a comprehensive summary:

I. Introduction

• The ultimate clinical trial goal is well-designed trials yielding robust evidence efficiently, reinforced by recent FDA guidance mandating increased attention to representative enrollment to improve generalizability, safety understanding, and equitable access.
• Prioritizing representativeness helps sponsors build operational plans informed by demographic insights, leading to more representative enrollment and generalizable data.

II. Benefits of Prioritizing Representativeness

• Scientific Benefits: Improved understanding of variability across demographic subgroups (e.g., race, ethnicity) impacting drug efficacy/safety; more thoughtful study design considering heterogeneity; identifying effect modifiers.
• Operational Benefits: Fine-tuning eligibility criteria, site selection, recruitment strategy via targeted site selection (e.g., focusing on specific populations within larger groups) and tailored outreach using real-world data (RWD) insights. Strategy: Characterize population subgroups, generate distribution estimates (with nuanced RWD caveats), set strategic enrollment goals.
• Regulatory Benefits: Demonstrating intentionality via DAPs improves application alignment; generalizable data is a key approvability factor; managing NDAs risk.
• Commercial Benefits: Better differentiation among prescribers/payers/patients; informing commercial strategy; potentially protecting price points through robust data supporting subpopulation effects.

III. How to Plan for a Representative Trial

• Characterize Differences Within the Patient Population: Conduct robust epidemiology assessments focusing on relevant demographic differences and variations in disease presentation/treatment patterns.
• Generate Distribution Estimates: Collaborate across medical/epidemiology/data teams to approximate relevant population distributions (with awareness of RWD limitations), learning from historical examples.
• Set Strategic Goals: Determine feasibility and adapt representativeness expectations based on regulatory, operational, and scientific evidence, involving cross-functional expertise.

IV. Selecting a Strategic Partner

• Look for partners with experience in DAPs (FDA guidance), access to multiple RWD sources, deep clinical/epidemiological analytical capability, cross-functional collaboration, regulatory awareness, and proven ability to connect diverse operational teams.

V. Conclusion/Future Outlook

• Proactive planning for representativeness yields tangible benefits even amidst evolving regulatory conditions.
• Interested parties can contact IQVIA or consult their services/platform.